Medtronic to Acquire Medical Device Company Contego Medical
Valued at $380 million, with potential payments post-acquisition, the deal will expand Medtronic's portfolio of carotid technologies and peripheral vascular devices.
Medtronic has announced its intent to acquire Contego Medical, a privately held medical device company focused on developing solutions for carotid artery disease and peripheral thrombectomy. Valued at $380 million, with potential payments post-acquisition, the deal will expand Medtronic's portfolio of carotid technologies and peripheral vascular devices.
The acquisition builds on Medtronic's exclusive US distribution agreement with Contego, first announced in January 2025, and aligns with its strategy of making targeted investments to strengthen its core franchises. The transaction is expected to expand patient access to therapies for carotid artery and peripheral vascular disease.
"With this acquisition, Medtronic is taking another important step to strengthen our leadership in the treatment of carotid artery disease," said David Moeller, senior vice president and president of Medtronic Peripheral Vascular Health, which is part of the company's cardiovascular portfolio. "By pairing Medtronic's deep clinical expertise in peripheral and neurovascular technologies with Contego's next-generation treatments backed by strong and consistent clinical data, we intend to become an undisputed leader in carotid revascularization."
Founded by Ravish Sachar, MD, and Jay Yadav, MD, Contego Medical develops technologies designed to address procedural challenges associated with carotid revascularization. Carotid artery disease involves the narrowing or blockage of arteries supplying blood to the brain and accounts for approximately 20% of ischemic strokes. During carotid revascularization, embolic debris released during treatment can contribute to procedural stroke risk.
The planned acquisition includes Contego's recently FDA-approved Neuroguard IEP Direct System, the first and only transcarotid artery revascularization system with integrated embolic protection (TCAR-IEP), in addition to flow reversal.
In the prospective, multicenter PERFORMANCE III study, the Neuroguard IEP Direct System reported the following 30-day outcomes:
- Zero strokes
- Zero neurological deaths
- Zero cranial nerve injuries
- Zero myocardial infarctions
"Contego was founded to address unmet needs in clinical practice by developing technologies designed to improve outcomes while simultaneously simplifying procedures. Deepening our partnership with Medtronic is an exciting next chapter," said Ravish Sachar, MD, founder and chief executive officer of Contego Medical. "We're proud of our team and grateful to the physicians, study sites, employees, and investors who helped bring these technologies to patients."
The deal also includes Contego's Excipio thrombectomy devices, which complement Medtronic's Liberant thrombectomy system for treating peripheral vascular disease.
"Stroke-related disability underscores the need for more innovative treatment options — and the opportunity to make a meaningful difference for patients," said Linnea Burman, senior vice president and president of Medtronic Neurovascular. "We are committed to delivering technologies designed to reduce stroke risk and advance patient care. Our planned acquisition of Contego builds on that commitment, helping physicians bring meaningful innovation to more patients with carotid artery disease."
Medtronic expects to complete the transaction in the third quarter of its fiscal year, subject to customary closing conditions. The acquisition is expected to be minimally dilutive to Medtronic's adjusted earnings per share (EPS) in FY27 and FY28 and neutral to accretive thereafter.
Stay tuned for more such updates on Digital Health News